Acorda Therapeutics
NASDAQ:
ACOR-USD
$0.52
0.00%
Acorda Therapeutics Inc (ACOR) is a publicly traded drug manufacturers - specialty and generic business based in the US which employs around 100 staff. Acorda Therapeutics is listed on the NASDAQ and traded in US dollars. Its current price of $0.52 is 95.7% down on its price a month ago ($12.1001).
How to buy shares in Acorda Therapeutics
- Choose a platform. If you're a beginner, our share trading platform picks below can help you choose.
- Open your account. Provide your personal information and sign up.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: ACOR in this case.
- Research shares. The platform should provide the latest information available.
- Buy your shares. Place a market order or limit order with your preferred number of shares. It's that simple.
Our top picks for where to buy Acorda Therapeutics shares
Capital at risk. Other fees apply.
Copy picks from top traders
- Commission-free stock trades
- Receive dividend payments
- Invest in fractional shares
Capital at risk. T&Cs apply.
Personalised market updates
- Commission-free trading
- Invest in fractional shares
- Over 5,400 stocks & ETFs
Capital at risk. T&Cs apply.
97% would recommend
- No commissions for funds
- Expert research and insights
- Wide range of tax wrappers
Fees calculator for buying Acorda Therapeutics shares with popular apps
Both exchange rates and share prices fluctuate in real time, so the costs estimated here should be considered as a guide only. They don't factor in spreads, which can be hard to pin down. Always refer to the platform itself for availability and pricing.
Quantity of shares
1000
| Platform | Finder score | Account fee | Min. initial deposit | Trade cost | Link |
|---|---|---|---|---|---|
 |
4.39 ★★★★★ |
£0 | $100 | £420.43 |
Go to siteCapital at risk
|
 |
4.3 ★★★★★ |
£0 | £0 | £420.43 |
Go to siteCapital at risk
|
 |
4.2 ★★★★★ |
£0 | £1 | £434.47 |
Go to siteCapital at risk
|
 |
4.34 ★★★★★ |
0% - 0.25% | £100 | N/A |
Go to siteCapital at risk
|
 |
4.1 ★★★★★ |
£0 | £0 | N/A |
Read reviewCapital at risk
|
 |
4.4 ★★★★★ |
£0 | £0 | £420.43 |
Read reviewCapital at risk
|
Full comparison of share dealing platforms
These providers cover a wide range of stocks, but we can't guarantee they'll all offer this stock.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Alternative ways to invest in Acorda Therapeutics
Buying shares in just one company is generally considered a riskier bet than investing in a range of investments - AKA a "diversified portfolio". Experts generally recommend holding a mix of investments in specific assets and funds. Funds are ready-made portfolios of multiple companies' shares (potentially including Acorda Therapeutics), and the idea is that drops in the value of one constituent company's share price might be offset by rises in others.
Acorda Therapeutics is a major part of the NASDAQ, so it's included in many global funds and investment trusts, as well as tracker-style exchange traded funds (ETFs).
Is it a good time to buy Acorda Therapeutics stock?
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Use our graph to track the performance of ACOR stocks over time.
Share price volatility
Over the last 12 months, Acorda Therapeutics's shares have ranged in value from as little as $0.6116 up to $24.196. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics's is 1.462. This would suggest that Acorda Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Historical closes compared with the last close of $0.52
| 1 week (2024-04-10) | -21.33% |
|---|---|
| 1 month (2024-03-21) | -95.70% |
| 3 months (2024-01-23) | -96.99% |
| 6 months (2023-10-23) | -94.87% |
| 1 year (2023-04-23) | 10.64% |
| 2 years (2022-04-20) | -63.64% |
| 3 years (2021-04-22) | -88.94% |
| 5 years (2019-04-23) | -95.34% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Invest in Acorda Therapeutics shares
Finder Award
- Start investing from $50
- Pay no stamp duty on UK shares
- Commission-free trading. Other fees may apply.
Go to site
Capital at risk
Other fees may apply
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is Acorda Therapeutics under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Acorda Therapeutics P/E ratio, PEG ratio and EBITDA
Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Acorda Therapeutics's PEG ratio in relation to those of similar companies.
Acorda Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.4 million (£0.0 million).
The EBITDA is a measure of a Acorda Therapeutics's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
- Citius Pharmaceuticals (CTXR.US): USD$-38820440
- KemPharm (KMPH.US): USD$-17723000
Sign up for weekly expert share tips
Join 100,000 subscribers who are notified about expert share tips. Plus a chance to win £800!
By signing up you agree to receive emails from Finder and to the privacy policy and terms & conditions.
Frequently asked questions
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
More guides on Finder
-
How to buy Canopy Growth shares
Ever wondered how to buy shares in Canopy Growth? We explain how and compare a range of providers that can give you access to many brands, including Canopy Growth.
-
How to buy Green Thumb Industries shares
Ever wondered how to buy shares in Green Thumb Industries? We explain how and compare a range of providers that can give you access to many brands, including Green Thumb Industries.
-
How to buy Curaleaf Holdings shares
Ever wondered how to buy shares in Curaleaf Holdings? We explain how and compare a range of providers that can give you access to many brands, including Curaleaf Holdings.
-
How to buy Genesis Healthcare shares
Ever wondered how to buy shares in Genesis Healthcare? We explain how and compare a range of providers that can give you access to many brands, including Genesis Healthcare.
-
How to buy Allergy Therapeutics shares
Ever wondered how to buy shares in Allergy Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Allergy Therapeutics.
-
How to buy 4D pharma shares
Ever wondered how to buy shares in 4D pharma? We explain how and compare a range of providers that can give you access to many brands, including 4D pharma.
-
How to buy Aurora Cannabis shares
Ever wondered how to buy shares in Aurora Cannabis? We explain how and compare a range of providers that can give you access to many brands, including Aurora Cannabis.
-
How to buy Evgen Pharma shares
Thinking about buying shares in Evgen Pharma? We explain how to do it and compare a range of providers who will give you access to global markets.
-
How to buy Intuitive Surgical shares
Ever wondered how to buy shares in Intuitive Surgical? We explain how and compare a range of providers that can give you access to many brands, including Intuitive Surgical.
-
How to buy Stryker Corporation shares
Ever wondered how to buy shares in Stryker? We explain how and compare a range of providers that can give you access to many brands, including Stryker.